Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis.


Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
04 May 2021
Historique:
received: 02 03 2021
accepted: 26 04 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 30 11 2021
Statut: epublish

Résumé

To assess the effects of daily adaptive MR-guided replanning in stereotactic body radiation therapy (SBRT) of liver metastases based on a patient individual longitudinal dosimetric analysis. Fifteen patients assigned to SBRT for oligometastatic liver metastases underwent daily MR-guided target localization and on-table treatment plan re-optimization. Gross tumor volume (GTV) and organs at risk (OARs) were adapted to the anatomy-of-the-day. A reoptimized plan (RP) and a rigidly shifted baseline plan (sBP) without re-optimization were generated for each fraction. After extraction of DVH parameters for GTV, planning target volume (PTV), and OARs (stomach, duodenum, bowel, liver, heart) plans were compared on a per-patient basis. Median pre-treatment GTV and PTV were 14.9 cc (interquartile range (IQR): 7.7-32.9) and 62.7 cc (IQR: 42.4-105.5) respectively. SBRT with RP improved PTV coverage (V100%) for 47/75 of the fractions and reduced doses to the most proximal OARs (D1cc, Dmean) in 33/75 fractions compared to sBP. RP significantly improved PTV coverage (V100%) for metastases within close proximity to an OAR by 4.0% (≤ 0.2 cm distance from the edge of the PTV to the edge of the OAR; n = 7; p = 0.01), but only by 0.2% for metastases farther away from OAR (> 2 cm distance; n = 7; p = 0.37). No acute grade 3 treatment-related toxicities were observed. MR-guided online replanning SBRT improved target coverage and OAR sparing for liver metastases with a distance from the edge of the PTV to the nearest luminal OAR < 2 cm. Only marginal improvements in target coverage were observed for target distant to critical OARs, indicating that these patients do not benefit from daily adaptive replanning.

Identifiants

pubmed: 33947429
doi: 10.1186/s13014-021-01813-6
pii: 10.1186/s13014-021-01813-6
pmc: PMC8097956
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

84

Références

Cancer. 2004 Oct 1;101(7):1623-31
pubmed: 15378503
Radiother Oncol. 2018 Mar;126(3):519-526
pubmed: 29277446
Brachytherapy. 2014 May-Jun;13(3):233-9
pubmed: 24559793
Lancet Oncol. 2015 Jun;16(6):630-7
pubmed: 25981812
Radiother Oncol. 2017 May;123(2):227-233
pubmed: 28274491
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):933-941
pubmed: 30928360
Cancer. 2015 Apr 1;121(7):1128-37
pubmed: 25538019
J Clin Oncol. 2009 Apr 1;27(10):1572-8
pubmed: 19255321
BMC Cancer. 2018 Mar 13;18(1):283
pubmed: 29534687
Acta Oncol. 2006;45(7):838-47
pubmed: 16982548
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):987-995
pubmed: 29953910
J Radiat Res. 2016 Aug;57 Suppl 1:i53-i57
pubmed: 27029741
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e423-9
pubmed: 22436785
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):426-433
pubmed: 29902559
Front Oncol. 2016 Oct 13;6:215
pubmed: 27790408
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Radiat Oncol. 2020 Aug 21;15(1):203
pubmed: 32825848
Comput Aided Surg. 2007 Sep;12(5):253-61
pubmed: 17957532
Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):394-403
pubmed: 26678659
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
J Thorac Oncol. 2012 Sep;7(9):1382-93
pubmed: 22843086

Auteurs

Michael Mayinger (M)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany. Michael.Mayinger@usz.ch.

Roman Ludwig (R)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Sebastian M Christ (SM)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Riccardo Dal Bello (R)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Alex Ryu (A)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Nienke Weitkamp (N)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Matea Pavic (M)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Helena Garcia Schüler (H)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Lotte Wilke (L)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Jan Unkelbach (J)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Stephanie Tanadini-Lang (S)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Nicolaus Andratschke (N)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH